打开APP

Debiotech公司和瑞士研究中心联合研究开发了新型的人工胰腺

  1. Debiotech
  2. 人工胰腺
  3. 监测
  4. 胰岛素
  5. 血糖

来源:生物谷 2015-11-27 18:37

近日,瑞士医疗科技旗下Debiotech公司同两个瑞士研究中心合作,共同开发出了针对糖尿病患者的新一代人工胰腺,研究者旨在通过利用一种微机电系统来控制胰岛素泵从而改善自动胰岛素运输设备的准确性,他们利用一种算法,根据测定患者机体的血糖水平、患者的时间以及调整胰岛素泵输注速率的预期活动来评估患者的需求。

2015年11月27日 讯 /生物谷BIOON/ --近日,瑞士医疗科技旗下Debiotech公司同两个瑞士研究中心合作,共同开发出了针对糖尿病患者的新一代人工胰腺,研究者旨在通过利用一种微机电系统来控制胰岛素泵从而改善自动胰岛素运输设备的准确性,他们利用一种算法,根据测定患者机体的血糖水平、患者的时间以及调整胰岛素泵输注速率的预期活动来评估患者的需求。

长期以来制造人工胰腺的障碍就是创建足够准确的血糖数据,并且分析胰岛素自动输注的相关数据;当前市场上连续的血糖监测胰岛素泵组合,比如美敦力公司的MiniMed,其需要用户自己决定胰岛素的剂量的使用时间,此外,计划所有的动态血糖监测系统(CGMs)都需要进行常规的每日校准,从而消除拥有这样设备的优势。

一种人工胰腺可以准确并且自动地输入适当水平的激素,包括胰岛素等,从而就可以帮助糖尿病患者更加容易地在规定范围内控制好自身的血糖水平,而且目前在研究与开发过程中存在很多种方法,但没有一种可以达到市场要求。伯尔尼大学医院(Bern University Hospital)的内分泌科主任Peter Diem在一份声明中指出,如今糖尿病患者需要遵循一种强制性的疗法,包括测定血糖、剂量计算及胰岛素注射等,而本文中的这种理念将会产生一种单一的系统,在不需要任何干预的情况下帮助指导这些操作。

这种系统将会包括JewelPump、Debiotech公司的微机电系统集成和一次性装置芯片技术,利用小型化、放水的补丁泵,其就可以在超过7天的时间里分配500U剂量的胰岛素,这种设备整合了一种小型设备app,其中就包括血糖监测阅读器和微型计算器,这种新型的人工胰腺算法也可以在无线PDA设备上运行。

在今年早些时候,Debiotech公司就获得了连续葡萄糖监测技术的许可,最后研究人员Stavroula Mougiakakou表示,我们提出的算法非常容易使用,其基于强化学习的基础引入了实时个体化的改变,针对病人机体内部的变化,其可以弥补不确定事件所带来的影响。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!转载请注明来源并附原文链接。更多资讯请下载生物谷APP.

生物谷推荐的新闻阅读:

Debiotech partners with Swiss academics to create a novel artificial pancreas

Swiss med tech player Debiotech has partnered to develop a next-gen artificial pancreas for diabetics with a pair of Swiss research centers. The aim is to improve upon the accuracy of automatic insulin delivery by using a microelectromechanical system (MEMS) to control the pump. It will be based on an algorithm designed to estimate patient needs based on their measured glucose levels, the time of day and anticipated activities to adjust the infusion rate from an insulin pump.

A long-standing barrier to marketing an artificial pancreas is creating sufficiently accurate blood glucose data and analysis of that data that the infusion of insulin is automatic.

Existing continuous glucose monitor-insulin pump combos, such as Medtronic's ($MDT) MiniMed, require users to make their own determinations regarding the amount and timing of an insulin dosage. In addition, almost all CGMs require routine, daily finger-sticks for calibration--thereby eliminating much of the advantage of having such a device.

An artificial pancreas is intended to accurately and automatically infuse the proper level of hormones, including insulin, to enable diabetics easily to maintain their glucose levels within prescribed ranges. And while several approaches are in the research and development stages, none have reached the market yet.

"Today, a diabetic patient must follow a very constraining therapy with many blood glucose measurements, dose calculations and insulin injections," Dr. Peter Diem, Head of the Division of Endocrinology, Diabetes and Clinical Nutrition of the Bern University Hospital, said in a statement. "The ideal would be to have a single system that can conduct all of these operations without requiring any intervention." That institution, along with the ARTORG Center for Biomedical Engineering Research of the University of Bern, are part of this partnership with Debiotech.

The system will include JewelPump, Debiotech's MEMS-integrated and disposable insulin-pump chip technology. With its miniaturized, watertight patch-pump it can dispense up to 500U of insulin over up to 7 days. The device integrates with a smart device app that includes a blood glucose monitor reader as well as bolus calculator. The new artificial pancreas algorithm will run on the wireless PDA device that's already used now to program the JewelPump.

Earlier this year, Debiotech gained an option to in-license continuous glucose monitoring technology that was formerly Bayer's; the company said at the time it would use in combination with the JewelPump to develop an artificial pancreas.

"Approaches taken so far do not resolve fundamental difficulties: the patients' variability, uncertainties related to system disturbances, e.g. food intake and physical activity, and errors related to the used devices,"Stavroula Mougiakakou, Head of the Diabetes Technology Research Group at the ARTORG Center, said in a statement.

He added, "The proposed algorithm is easy to use, introduces the concept of real-time personalisation based on reinforcement learning, a machine learning method, is able to tackle inter- and intra-patient variability, and can compensate for the effects of uncertain events."

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->